AMEX:CVRS

Stock Analysis Report

Corindus Vascular Robotics

Executive Summary

Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally.


Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has Corindus Vascular Robotics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CVRS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.2%

CVRS

10.2%

US Medical Equipment

9.4%

US Market


1 Year Return

268.1%

CVRS

2.1%

US Medical Equipment

-6.8%

US Market

Return vs Industry: CVRS exceeded the US Medical Equipment industry which returned 28.4% over the past year.

Return vs Market: CVRS exceeded the US Market which returned 24.7% over the past year.


Shareholder returns

CVRSIndustryMarket
7 Day-0.2%10.2%9.4%
30 Day-0.2%0.9%-3.9%
90 Day78.7%-12.1%-16.5%
1 Year268.1%268.1%2.9%2.1%-4.8%-6.8%
3 Year472.2%472.2%57.1%52.9%23.4%15.2%
5 Year6.8%6.8%89.2%69.8%41.3%25.7%

Price Volatility Vs. Market

How volatile is Corindus Vascular Robotics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Corindus Vascular Robotics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Corindus Vascular Robotics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Corindus Vascular Robotics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Corindus Vascular Robotics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

31.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CVRS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CVRS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CVRS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CVRS's revenue (42.5% per year) is forecast to grow faster than the US market (7.5% per year).

High Growth Revenue: CVRS's revenue (42.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CVRS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Corindus Vascular Robotics performed over the past 5 years?

-12.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CVRS is currently unprofitable.

Growing Profit Margin: CVRS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CVRS is unprofitable, and losses have increased over the past 5 years at a rate of -12.5% per year.

Accelerating Growth: Unable to compare CVRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CVRS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31%).


Return on Equity

High ROE: CVRS has a negative Return on Equity (-198.27%), as it is currently unprofitable.


Next Steps

Financial Health

How is Corindus Vascular Robotics's financial position?


Financial Position Analysis

Short Term Liabilities: CVRS's short term assets ($39.7M) exceed its short term liabilities ($13.2M).

Long Term Liabilities: CVRS's short term assets ($39.7M) exceed its long term liabilities ($11.7M).


Debt to Equity History and Analysis

Debt Level: CVRS's debt to equity ratio (80.5%) is considered high.

Reducing Debt: CVRS's debt to equity ratio has reduced from 484.7% to 80.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CVRS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CVRS has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of -6.2% each year.


Next Steps

Dividend

What is Corindus Vascular Robotics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CVRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CVRS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CVRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CVRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CVRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Mark Toland (49yo)

3.58s

Tenure

US$2,194,146

Compensation

Mr. Mark J. Toland has been the Chief Executive Officer, President and Director of Corindus Vascular Robotics, Inc. since March 7, 2016. Mr. Toland joined Corindus from Boston Scientific Corporation, a glo ...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD2.19M) is about average for companies of similar size in the US market ($USD2.53M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Mark Toland
CEO, President & Director3.58yrsUS$2.19mno data
David Long
CFO, Senior VP5.17yrsUS$568.37kno data
Douglas Teany
Chief Operating Officer3.58yrsUS$1.04mno data
Nora Dutta
Senior Vice President of Human Resources3.5yrsno datano data
J. Grantham
Chief Medical Officer of Cardiovascular3.17yrsno datano data
Aquilla Turk
Chief Medical Officer of Neuroendovascular1.25yrsno datano data
Martin Leon
External Consultant & Executive Advisor3.5yrsno datano data

3.5yrs

Average Tenure

49yo

Average Age

Experienced Management: CVRS's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mark Toland
CEO, President & Director3.58yrsUS$2.19mno data
James Tobin
Independent Director1.58yrsUS$48.06k0.041% $364.5k
Jeffrey Lightcap
Independent Chairman of the Board5.17yrsno datano data
Douglas Braunstein
Independent Director1.58yrsUS$48.89k0.038% $335.5k
Louis Cannon
Independent Director2.58yrsUS$60.00k0.13% $1.2m
Jeffrey Gold
Independent Director5.17yrsUS$67.00k0.045% $403.1k
Campbell Rogers
Independent Director3.58yrsUS$59.00k0.033% $296.4k
Nathan Harrington
Director2.33yrsUS$51.00k0.033% $296.4k

3.1yrs

Average Tenure

59yo

Average Age

Experienced Board: CVRS's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.


Top Shareholders

Company Information

Corindus Vascular Robotics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Corindus Vascular Robotics, Inc.
  • Ticker: CVRS
  • Exchange: AMEX
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$891.087m
  • Shares outstanding: 208.69m
  • Website: https://www.corindus.com

Number of Employees


Location

  • Corindus Vascular Robotics, Inc.
  • 309 Waverley Oaks Road
  • Suite 105
  • Waltham
  • Massachusetts
  • 2452
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CVRSAMEX (NYSE MKT LLC)YesNew Common StockUSUSDAug 2014
CR3DB (Deutsche Boerse AG)YesNew Common StockDEEURAug 2014

Biography

Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures. Its CorPath system allows the physician to perform procedures with a control console located within an interventional cockpit; and CorPath GRX system enables the precise robotic-assisted control of guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/30 00:29
End of Day Share Price2019/10/28 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.